Larazotide

Mechanism of Action

Larazotide acetate is an octapeptide that acts as a competitive antagonist of zonulin at the intestinal tight junction. Zonulin is the only known physiological regulator of intestinal permeability, and its dysregulation is associated with various autoimmune and inflammatory conditions.

Zonulin and Tight Junctions

What is Zonulin?

Zonulin (also known as pre-haptoglobin 2) is a protein that modulates tight junctions between intestinal epithelial cells:

• Released in response to certain triggers (gluten, bacteria)
• Binds to receptors on epithelial cells
• Opens tight junctions, increasing permeability
• Allows passage of larger molecules through the gut barrier

Tight Junction Biology

Tight junctions are protein complexes that seal the space between epithelial cells:

• Composed of claudins, occludin, and ZO proteins
• Regulate paracellular transport
• When disrupted, allow antigens and pathogens into submucosa

How Larazotide Works

Competitive Antagonism

Larazotide competes with zonulin for binding sites:

• Structurally similar to the zonulin active site
• Prevents zonulin from binding to its receptor
• Keeps tight junctions closed and functional

Local Gut Activity

Critically, larazotide works locally in the intestine:

• Minimal systemic absorption (less than 1%)
• Acts directly on intestinal epithelium
• Degraded in the gut lumen
• Very low systemic side effect profile

Downstream Effects

Prevention of Antigen Translocation

• Reduces passage of gluten peptides through gut wall
• Decreases immune activation in celiac disease
• May reduce inflammation from other dietary antigens

Inflammation Reduction

• Less antigen exposure means less immune response
• Reduced cytokine production
• Decreased intestinal inflammation

Research & Evidence

Phase 3 Clinical Trials

CeliAction Study (Phase 3)

The pivotal trial for celiac disease:

• 342 patients with celiac disease on gluten-free diet
• Randomized to larazotide 0.5mg TID or placebo
• Primary endpoint: Reduction in symptoms and days with symptoms
• Results: Significant reduction in symptoms vs placebo

Key Findings

• 26% reduction in symptom days
• Improvement in abdominal pain, bloating, tiredness
• Well-tolerated with adverse event profile similar to placebo
• Effective as adjunct to gluten-free diet

Phase 2 Studies

Dose-Finding Studies

Multiple Phase 2 trials established optimal dosing:

• Doses from 0.25mg to 8mg TID tested
• 0.5mg TID showed optimal benefit/risk
• Higher doses did not improve efficacy
• Confirmed local (non-systemic) mechanism

Gluten Challenge Studies

Studies where patients were deliberately exposed to gluten:

• Larazotide reduced GI symptoms after gluten exposure
• Reduced intestinal permeability measured by lactulose/mannitol test
• Decreased gluten-induced tight junction changes

Mechanistic Studies

Tight Junction Imaging

Biopsy studies showed:

• Preservation of tight junction structure with larazotide
• Reduced zonulin-mediated opening
• Maintained claudin and occludin organization

Permeability Testing

Functional permeability studies demonstrated:

• Reduced lactulose absorption (marker of permeability)
• Maintained mannitol absorption (transcellular route)
• Indicates specific tight junction protection

Beyond Celiac Disease

Other Conditions Under Investigation

• Non-celiac gluten sensitivity
• Irritable bowel syndrome
• Type 1 diabetes (permeability link)
• General "leaky gut" conditions

Dosing

Clinical Trial Protocols

Administration Guidelines

Timing with Meals

Critical for efficacy:

• Must be taken 15 minutes before meals
• Allows peptide to be present when food triggers zonulin release
• Most effective when taken before gluten exposure

Meal Association

• Take with breakfast, lunch, and dinner
• Skip dose if skipping meal
• Not effective if taken without food

Formulation

• Oral capsule (clinical trial formulation)
• Designed for gastric stability
• Releases in small intestine where it acts
• No reconstitution required

Pharmacokinetics

Absorption

• Oral: Designed for minimal absorption
• Less than 1% systemic bioavailability
• Acts locally in intestinal lumen
• Peak local concentration: ~1 hour post-dose

Distribution

• Remains primarily in GI tract
• Minimal plasma levels detectable
• Does not distribute systemically to any significant degree
• This is a feature, not a bug (reduces systemic side effects)

Metabolism

• Degraded by intestinal peptidases
• No hepatic metabolism (not absorbed)
• No CYP450 interactions
• No systemic drug interactions expected

Elimination

• Fecal elimination of parent compound and metabolites
• Duration of local effect: 3-4 hours
• Multiple daily dosing required for coverage
• No accumulation with repeated dosing

Synergy & Stacking

Gut Health Protocols

With BPC-157

Comprehensive gut repair approach:

• Larazotide: Prevents increased permeability
• BPC-157: Actively heals damaged gut lining
• Combined: Protection + repair

With KPV

Anti-inflammatory combination:

• Larazotide: Reduces antigen exposure
• KPV: Reduces inflammatory response to antigens
• Useful for inflammatory bowel conditions

With Probiotics

Microbiome support:

• Healthy bacteria produce short-chain fatty acids
• SCFAs support tight junction integrity
• Larazotide provides additional protection

Lifestyle Synergies

With Gluten-Free Diet

Essential combination for celiac:

• Diet removes primary trigger
• Larazotide provides additional protection
• Addresses accidental gluten exposure

With Elimination Diet

For identifying food triggers:

• Larazotide may provide protection during reintroduction
• Allows clearer identification of triggers
• Reduces confounding from permeability effects

What to Avoid

• Intentional gluten consumption (defeats purpose)
• Assuming larazotide allows unrestricted gluten (it doesn't)
• NSAIDs (independent gut damage)

Safety & Side Effects

Clinical Trial Safety Data

Adverse Events (Similar to Placebo)

• Headache: 6.5% (vs 6.2% placebo)
• Upper respiratory infection: 5.3% (vs 4.7% placebo)
• Urinary tract infection: 3.5% (vs 3.1% placebo)
• Nausea: 2.4% (vs 2.5% placebo)

Gastrointestinal Effects

• Generally well-tolerated
• No increased GI adverse events vs placebo
• Some patients report reduced symptoms (intended effect)

Why Safety Profile is Favorable

Minimal Systemic Exposure

• Less than 1% absorbed
• No systemic drug levels
• Limited potential for systemic toxicity

Local Mechanism

• Acts only in gut lumen
• Does not affect other organ systems
• Mechanism is competitive antagonism (reversible)

Long-Term Safety

Clinical Trial Data

• Up to 12-week treatment periods in trials
• No serious adverse events attributed to larazotide
• Long-term extension studies ongoing

Monitoring

Before Starting

Celiac Disease Confirmation

• Confirm diagnosis with serology and biopsy
• Ensure patient is on gluten-free diet
• Document baseline symptoms

Baseline Assessment

• Symptom diary (pain, bloating, etc.)
• Quality of life assessment
• Consider baseline celiac serology

During Treatment

Symptom Tracking

• Daily symptom diary recommended
• Track meal timing and content
• Note any accidental gluten exposures

Compliance Monitoring

• Ensure three-times-daily dosing
• Confirm timing with meals
• Assess gluten-free diet adherence

Follow-Up

Clinical Response

• Symptom improvement expected within 2-4 weeks
• No blood tests to monitor drug levels
• Celiac serology for disease monitoring (not drug monitoring)

Regulatory Status

Current Status

Development Timeline

• 2000s: Discovery and preclinical development
• 2010-2015: Phase 2 clinical trials
• 2016-2020: Phase 3 trials
• 2020s: Regulatory submissions
• Future: Potential first zonulin antagonist approval

Availability

• Currently only available through clinical trials
• Not yet approved for prescription use
• Research chemical versions may exist but are not recommended
• Pharmaceutical-grade formulation expected upon approval

References